Clinical Trials
4
Active:1
Completed:3
Trial Phases
1 Phases
Phase 1:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (100.0%)A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects
Phase 1
Completed
- Conditions
- Autoimmune Diseases
- Interventions
- Drug: Placebo-matched MoxifloxacinDrug: Placebo-matched CBP-307
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Connect Biopharma Australia Pty Ltd
- Target Recruit Count
- 112
- Registration Number
- NCT04818229
- Locations
- 🇺🇸
Clinical Pharmacology of Miami (CPMI), LLC, Hialeah, Florida, United States
🇦🇺CMAX, Adelaide, South Australia, Australia
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Connect Biopharma Australia Pty Ltd
- Target Recruit Count
- 74
- Registration Number
- NCT04811469
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
News
No news found